このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Zai Lab 過去の業績

過去基準チェック /06

Zai Labの収益は年間平均-14%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 51.6%割合で増加しています。

主要情報

-9.5%

収益成長率

-2.2%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	48.3%
株主資本利益率	-42.4%
ネット・マージン	-92.4%
前回の決算情報	30 Jun 2024

Recent updates

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Sep 23

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Jun 12

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

May 14

A Risky Bet: Zai Lab's Uncertain Future

Apr 16

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24

収支内訳

Zai Lab の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:ZLAB 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	323	-298	300	0
31 Mar 24	291	-339	288	0
31 Dec 23	267	-335	282	0
30 Sep 23	263	-301	271	0
30 Jun 23	252	-393	269	0
31 Mar 23	231	-410	264	0
31 Dec 22	215	-443	259	0
30 Sep 22	197	-593	257	0
30 Jun 22	182	-529	249	0
31 Mar 22	171	-554	240	0
31 Dec 21	144	-704	219	0
30 Sep 21	115	-569	190	-160
30 Jun 21	87	-537	159	-102
31 Mar 21	61	-454	128	-34
31 Dec 20	49	-269	111	0
30 Sep 20	39	-239	93	192
30 Jun 20	29	-240	83	185
31 Mar 20	19	-201	74	146
31 Dec 19	13	-195	70	0
30 Sep 19	8	-212	58	166
30 Jun 19	4	-181	45	145
31 Mar 19	2	-160	33	132
31 Dec 18	0	-139	22	120
30 Sep 18	0	-89	14	74
30 Jun 18	0	-67	14	53
31 Mar 18	0	-59	13	46
31 Dec 17	0	-50	12	39
30 Sep 17	0	-50	10	41
30 Jun 17	0	-50	8	44
31 Mar 17	0	-44	7	38
31 Dec 16	0	-38	6	32

質の高い収益: ZLABは現在利益が出ていません。

利益率の向上: ZLABは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ZLABは利益が出ておらず、過去 5 年間で損失は年間14%の割合で増加しています。

成長の加速: ZLABの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ZLABは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: ZLABは現在利益が出ていないため、自己資本利益率 ( -44.47% ) はマイナスです。

Zai Lab 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023)

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Recent updates

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Insider notifies of intention to sell stock

Consensus estimates of losses per share improve by 16%

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023)

Forecast to breakeven in 2026

A Risky Bet: Zai Lab's Uncertain Future

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Price target decreased by 11% to US$56.44

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Key Executive notifies of intention to sell stock

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Consensus EPS estimates upgraded to US$3.45 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

New minor risk - Profitability

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Insider exercised options to buy US$295k worth of stock.

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

New minor risk - Share price stability

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib

Consensus EPS estimates upgraded to US$3.21 loss

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder exercised options to buy US$292k worth of stock.

Forecast to breakeven in 2025

Insider exercised options and sold US$425k worth of stock

Full year 2022 earnings released: US$4.62 loss per share (vs US$7.58 loss in FY 2021)

Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?

Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration

Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans

Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Independent Director recently sold US$278k worth of stock

Insider notifies of intention to sell stock

Consensus EPS estimates fall by 16%

過去基準チェック /06